Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
article
Learning to determine the value technological advance has contributed requires a great degree of sophistication, Randall Rader said in a session on protecting biotechnology innovations in the US and Latin America at the 2014 BIO International Convention in San Diego, California, yesterday (Tuesday).   25 June 2014
Americas
The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the USPTO, according to a report presented to the 2014 BIO International Convention in San Diego today.   25 June 2014
Americas
The Indian Patent Office has rejected a patent application for an anti-cancer drug for the second time, paving the way for generic versions to potentially enter the market.   24 June 2014
Americas
Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol.   23 June 2014
Americas
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli.   20 June 2014
Biotechnology
Digital health, which brings together digital and genetic data to improve healthcare, will play a vital role in personalised medicine. But there will be significant challenges when it comes to protecting this innovative new area. LSIPR looks at its uses and the potential challenges.   20 June 2014
Americas
The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.   20 June 2014
Biotechnology
For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts.   20 June 2014
Americas
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.   20 June 2014
Biotechnology
The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel.   20 June 2014